The FDA has savaged China’s Zhejiang Hisoar Pharmaceutical site in Taizhou City in a warning saying the company did not routinely do microbial testing on APIs shipped to the U.S., but did routinely delete other failed impurities tests that would have kept batches from being acceptable for sale.
